Research programme: Proto oncogene protein-c bcl-2 inhibitors - Ascenta Therapeutics
Alternative Names: BI 33Latest Information Update: 16 Jul 2016
At a glance
- Originator Ascenta Therapeutics
- Class Flavonoids
- Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 07 Nov 2007 Preclinical trials in Cancer in USA (unspecified route)